20 Million Patients Benefit from da Vinci Surgery Globally
Rhea-AI Summary
Intuitive (NASDAQ: ISRG) announced that more than 20 million patients worldwide have undergone surgery using da Vinci systems, a milestone reached at the end of 2025. In 2025 alone, clinicians performed over 3.1 million da Vinci procedures. The company highlighted platform advances including da Vinci 5 (claimed >10,000x computing power), da Vinci Single Port expansion of indications, and Ion robotic bronchoscopy, used in >140,000 lung biopsies in 2025. Intuitive said these volumes inform technology, training, and system improvements aimed at expanding access to minimally invasive care.
Positive
- > 20 million patients treated worldwide with da Vinci systems
- > 3.1 million da Vinci procedures performed in 2025
- Ion robotic bronchoscopy used in > 140,000 lung biopsies in 2025
- da Vinci 5 reported to deliver > 10,000x computing power vs predecessor
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ISRG is modestly up (+0.4%) while peers are mixed: ALC slightly positive (+0.11%) but RMD, HOLX, and WST show declines (down to -3.28%). This supports a stock‑specific move around the da Vinci milestone.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Prelim 2025 earnings | Positive | -2.7% | Preliminary Q4 and FY2025 results with strong revenue and procedure growth. |
| Dec 10 | SP indication expansion | Positive | -1.5% | FDA clearance expanding U.S. indications for da Vinci SP procedures. |
| Oct 21 | Q3 2025 earnings | Positive | +0.9% | Q3 2025 revenue growth, higher procedures, and installed base expansion. |
| Oct 08 | Ion AI update | Positive | +1.6% | FDA‑cleared AI navigation and imaging upgrade for the Ion system. |
| Oct 07 | Portfolio company funding | Positive | -1.9% | Jupiter Endovascular oversubscribed Series B financing above <b>$40M</b> target. |
Recent positive product and earnings news often saw mixed reactions, with three negative and two positive one‑day moves.
Over the past several months, Intuitive reported strong growth and expanding clinical adoption. Preliminary Q4 and FY2025 results on Jan 14, 2026 highlighted FY2025 revenue of ~$10.06B and ~3,153,000 da Vinci procedures. Earlier, Q3 2025 revenue reached $2.51B with robust procedure growth. The da Vinci SP platform gained expanded U.S. indications on Dec 10, 2025, and Ion saw AI and imaging enhancements, framing today’s 20‑million‑procedure milestone as part of a sustained adoption trajectory.
Market Pulse Summary
This announcement underscores scale and adoption across Intuitive’s platforms, with surgeons performing more than 20 million cumulative da Vinci procedures and over 3.1 million in 2025 alone. Ion contributed more than 140,000 lung biopsies in 2025, and da Vinci 5 brought a computing leap of over 10,000x versus Xi. In context of recent earnings strength and regulatory clearances, key watchpoints remain procedure growth, system placements, and continued platform innovation.
Key Terms
minimally invasive medical
robotic-assisted surgery medical
bronchoscopy medical
AI-generated analysis. Not financial advice.
Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive technologies
SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that more than 20 million patients worldwide have been operated on by surgeons using da Vinci surgical systems.
The milestone was reached as of the end of 2025, with more than 3.1 million da Vinci procedures performed last year alone. This achievement reflects the continued adoption of, and expanded patient access to, Intuitive’s minimally invasive technology.
“This achievement is a direct result of the dedication of surgeons and care teams around the globe to provide the best possible care for their patients,” said Intuitive chief executive officer Dave Rosa. “It underscores our belief in a future of care that is less invasive and profoundly better. For 30 years, we’ve worked toward that vision and we look forward to continuing our journey to help improve outcomes for patients everywhere.”
With experience drawn from 20 million procedures, Intuitive is uniquely positioned to translate insights from real-world use into technology, training, and system enhancements—supporting continuous innovation and helping healthcare systems improve outcomes, reduce variability and deliver high-quality care safely and effectively.
Innovation Across Platforms and Ecosystems
Intuitive’s dedication to innovation is reflected throughout its robotic-assisted platforms and their surrounding ecosystems, each designed to help physicians and hospital teams pursue their goals of improving clinical outcomes, enhancing patient and care team experiences, lowering the total cost of care, and expanding access to high-quality, minimally invasive care:
- da Vinci 5, the company’s latest system, delivers more than 10,000x the computing power of its predecessor, da Vinci Xi, unlocking new hardware and software capabilities to help enhance patient care.
- da Vinci Single Port (SP) continues to expand indications globally, enabling more procedures to be performed through a single incision.
- Ion, Intuitive’s robotic-assisted bronchoscopy platform, was used by physicians to perform more than 140,000 lung biopsies in 2025, with evidence showing its use could help patients with suspected lung cancer receive an early diagnosis.
Each of these platforms is supported by an ecosystem that includes advanced training, program optimization and ongoing collaborations that can help hospitals and care teams deliver high-quality, minimally invasive care safely and effectively.
“While we are proud of what has been accomplished to date, we are focused on the future because we believe the opportunity to impact the lives of more patients is significant,” added Rosa.
About Intuitive
Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About da Vinci Surgical Systems
There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
About the Ion Endoluminal System
The Ion Endoluminal System is a robotic-assisted, catheter-based platform that utilizes instruments and accessories for which the first cleared indication is minimally invasive biopsies in the lung. The system features an ultra-thin, ultra-maneuverable catheter that can articulate 180 degrees in all directions and allows navigation far into the peripheral lung and provides the stability necessary for precision in a biopsy. Information provided by the Ion Endoluminal System or its components should be considered guidance only and not replace clinical decisions made by a trained physician.
For more information, please visit the company’s website at www.intuitive.com.
Important Safety Information
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market. For summary of the risks associated with surgery and bronchoscopy refer to www.intuitive.com/safety.
Forward-Looking Statements
This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements.
These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, integration of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals.
These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Contact Information:
+1 408-523-8181 ext. 6934681
FAQ
What milestone did Intuitive (ISRG) announce on January 23, 2026?
How many da Vinci procedures did Intuitive report for 2025 (ISRG)?
What clinical usage did Intuitive report for its Ion system in 2025 (ISRG)?
What technology improvement did Intuitive highlight for da Vinci 5 (ISRG)?
Does the 20 million milestone indicate broader access to minimally invasive surgery (ISRG)?
